S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
Log in

TherapeuticsMD, Inc. (NASDAQ:TXMD) Receives Consensus Rating of "Buy" from Analysts

Last updated on Thursday, February 25, 2021 | 2021 MarketBeat

TherapeuticsMD, Inc. (NASDAQ:TXMD) has earned a consensus rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $6.29.

A number of brokerages have recently weighed in on TXMD. Zacks Investment Research raised TherapeuticsMD from a "hold" rating to a "buy" rating and set a $1.25 target price on the stock in a research report on Friday, November 13th. HC Wainwright reduced their price objective on TherapeuticsMD from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, January 28th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of TherapeuticsMD in a research report on Tuesday, November 10th.

A number of institutional investors and hedge funds have recently modified their holdings of TXMD. Morgan Stanley boosted its position in TherapeuticsMD by 6,296.3% during the fourth quarter. Morgan Stanley now owns 9,278,408 shares of the company's stock worth $11,227,000 after acquiring an additional 9,133,350 shares during the last quarter. Laurion Capital Management LP acquired a new position in shares of TherapeuticsMD in the 4th quarter valued at about $4,006,000. BlackRock Inc. lifted its position in TherapeuticsMD by 14.6% in the 4th quarter. BlackRock Inc. now owns 21,419,273 shares of the company's stock valued at $25,918,000 after purchasing an additional 2,727,622 shares during the last quarter. Handelsbanken Fonder AB bought a new stake in shares of TherapeuticsMD during the 3rd quarter worth about $3,925,000. Finally, Virtu Financial LLC bought a new stake in shares of TherapeuticsMD in the 4th quarter worth approximately $687,000. Institutional investors own 52.56% of the company's stock.

TXMD opened at $1.63 on Thursday. The company has a market capitalization of $488.62 million, a P/E ratio of -2.30 and a beta of 2.19. The stock has a fifty day moving average of $1.65 and a 200-day moving average of $1.46. TherapeuticsMD has a fifty-two week low of $0.85 and a fifty-two week high of $2.75.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

See Also: The four types of profit margin

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


20 Stocks to Sell Now

Most people know that brokerage rankings are overstated because of pressure from publicly-traded companies. No investor relations person wants to see "hold" and "sell" ratings issued for their stock. In reality, a "buy" rating really means "hold." "Hold" ratings really mean "sell" and "sell" ratings mean get out while you still can.

If Wall Street's top analysts are consistently giving "hold" and "sell" ratings to stock, you know there's a serious problem. We've compiled a list of the companies that Wall Street's top equities research analysts are consistently giving "hold" and "sell" ratings to. If you own one of these stocks, consider getting out while there's still time.

This slide show lists the 20 companies that have the lowest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

View the "20 Stocks to Sell Now".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.